Dayvigo Cost in Utah 2026: Price, Insurance, and Compounding Options

What Does Dayvigo Actually Cost in Utah Right Now?

The out-of-pocket cost for Dayvigo in Utah depends heavily on whether you use insurance, a manufacturer savings card, or a cash-pay discount program. The Eisai list price sits at $320 per month, but Utah retail pharmacies average roughly $85 per month for cash-pay patients in 2026 when GoodRx-type coupons or direct pharmacy discount programs are applied.

Lemborexant (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) approved by the FDA on December 20, 2019, for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance in adults [1]. It blocks orexin-1 and orexin-2 receptors, which are the primary wake-promoting neurochemical signals in the brain, rather than activating GABA pathways the way traditional benzodiazepines and Z-drugs do [2].

The FDA label specifies two approved doses: 5 mg and 10 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before planned awakening [1]. Starting at 5 mg is recommended, with the option to increase to 10 mg based on clinical response and tolerability. Because lemborexant is a Schedule IV controlled substance under the Controlled Substances Act, prescriptions carry specific regulatory requirements that affect telehealth and compounding access [3].

Price variability across Utah is real. A 30-tablet supply of Dayvigo 10 mg at a Salt Lake City Walgreens will quote a different cash price than a smaller independent pharmacy in Provo or St. George. Using a pharmacy benefits comparison tool or calling pharmacies directly with a GoodRx or SingleCare coupon code almost always produces a price well below the list price. The $85 average cited above represents a reasonable mid-range benchmark, not a guaranteed floor.

Utah Medicaid and Dayvigo: What the Formulary Actually Says

Utah Medicaid does not cover Dayvigo in 2026. The Utah Department of Health and Human Services administers the state Medicaid program (known as Medicaid and CHIP), and Dayvigo appears as a non-covered drug on the preferred drug list for insomnia [4].

This is a consistent pattern nationally. Many state Medicaid programs have not added DORAs to formulary because lower-cost generics for insomnia (including zolpidem, trazodone, and doxepin) remain available. The American Academy of Sleep Medicine 2017 Clinical Practice Guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, with pharmacotherapy reserved for patients who do not respond to or cannot access CBT-I [5]. Medicaid programs typically use that hierarchy to justify limiting coverage of branded sleep medications.

If you are a Utah Medicaid enrollee who has failed CBT-I and multiple generic sleep agents, a prescriber can submit a prior authorization (PA) request with clinical documentation. PA approvals for non-covered drugs under Utah Medicaid are rare but not impossible, particularly when generic alternatives are contraindicated. The PA form requires documentation of at least two failed therapeutic alternatives.

Private commercial insurance in Utah shows a different picture. Most major carriers (SelectHealth, DMBA, University of Utah Health Plans, Regence BlueCross BlueShield of Utah) list Dayvigo on formulary at Tier 3 or Tier 4, which typically means a $60 to $150 copay per month after deductible, depending on the specific plan year and benefit design [6]. Checking your Summary of Benefits and Coverage (SBC) document, or calling the member services number on your insurance card, is the fastest way to confirm your specific tier placement.

How the Eisai Savings Card Works in Utah

The Eisai patient savings card can reduce out-of-pocket cost for commercially insured patients in Utah to as low as $0 per month, subject to program terms. Eisai's copay assistance program for Dayvigo is available to patients who have commercial insurance (not Medicaid, Medicare Part D, or any federal program) and who meet income eligibility criteria [7].

The mechanics are straightforward. After enrollment at the Dayvigo manufacturer website, the patient receives a savings card (physical or digital). The card is presented at the pharmacy alongside the commercial insurance benefit. The manufacturer pays the difference between the insurance copay and the program cap. For 2026, Eisai has maintained a $0 copay offer for eligible commercially insured patients for up to 12 months of treatment.

Medicare Part D enrollees in Utah cannot use the Eisai savings card because of federal anti-kickback statute prohibitions on manufacturer copay assistance for government-insured patients [7]. Medicare beneficiaries should instead request a formulary exception from their Part D plan or ask their prescriber to document medical necessity for lemborexant versus covered alternatives such as low-dose doxepin (Silenor, available generic) or suvorexant (Belsomra), which is also a DORA but has been available longer and appears on more Part D formularies.

The Clinical Evidence Behind Lemborexant: SUNRISE-1 and SUNRISE-2

Understanding the evidence helps clinicians and patients make a case for coverage. The key trial supporting FDA approval was SUNRISE-1, a phase 3 randomized controlled trial published in JAMA Network Open in 2019 (N=291) that compared lemborexant 5 mg, lemborexant 10 mg, and placebo over 1 month, with an active comparator arm using zolpidem extended-release 6.25 mg [8]. Lemborexant 10 mg produced a mean reduction in subjective sleep onset latency (sSOL) of 21.9 minutes from baseline versus 9.8 minutes for placebo (P<0.001) [8]. Both lemborexant doses also outperformed zolpidem ER on wake after sleep onset (WASO) in the second half of the night, suggesting a particular advantage for sleep maintenance at the end of the sleep period.

SUNRISE-2, a 12-month trial (N=949), confirmed durability of effect and established the long-term safety profile, with no evidence of rebound insomnia or withdrawal on discontinuation [9]. The most common adverse event was somnolence, reported in 10% of patients on lemborexant 10 mg versus 2% on placebo [9]. Next-morning driving impairment, a key regulatory concern with sedative-hypnotics, was evaluated in a separate FDA-required study and found to be dose-dependent but within acceptable limits at 5 mg for most patients [1].

The American Academy of Sleep Medicine guideline authors wrote: "We suggest that clinicians use lemborexant as a treatment for sleep onset and sleep maintenance insomnia in adults," rating the evidence as moderate quality with a conditional recommendation [5]. That conditional status, rather than strong, reflects the limited head-to-head data against CBT-I rather than any safety concern.

These trial results matter for Utah patients navigating insurance. A prescriber's prior authorization letter that cites the SUNRISE-1 P<0.001 sleep onset data and the 12-month durability from SUNRISE-2 gives the insurance medical director a concrete clinical basis for approval [8][9].

Is Compounded Lemborexant Legal in Utah?

Compounded lemborexant from a licensed 503A pharmacy in Utah is legal, though it comes with important regulatory nuances that patients and prescribers must understand before proceeding.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed prescriber [10]. Utah has its own pharmacy practice rules administered by the Utah Division of Occupational and Professional Licensing (DOPL), which require compounding pharmacies to comply with both state and federal standards [11]. A 503A compounding pharmacy in Utah may compound lemborexant if a licensed prescriber provides a patient-specific prescription, the compounding does not copy a commercially available product without documented clinical rationale, and the pharmacy uses pharmaceutical-grade API (active pharmaceutical ingredient) that meets USP standards.

The phrase "does not copy a commercially available product" is the key regulatory friction point. Because Dayvigo is commercially available in 5 mg and 10 mg tablets, a 503A pharmacy technically cannot compound those exact same doses without clinical justification (for example, a patient with a documented swallowing disorder requiring a liquid formulation, or a documented allergy to an excipient in the commercial tablet). A prescriber who documents a legitimate clinical reason for a compounded preparation provides the legal basis for the 503A pharmacy to proceed [10].

Cost is the primary driver of patient interest in compounded lemborexant. Where a licensed Utah 503A pharmacy can legally compound the drug for a specific patient, the out-of-pocket cost may approach $0 to $30 per month compared to $85 or more at retail. Patients should confirm that their compounding pharmacy holds a current Utah DOPL license and that the pharmacist is willing to verify the API source documentation before dispensing.

Compounded lemborexant is not FDA-approved. It has not undergone the bioequivalence testing that Eisai's Dayvigo has. The clinical trials cited above were conducted with the commercial formulation only [8][9].

Telehealth Prescribing of Dayvigo in Utah: What You Need to Know

Telehealth prescribing of Dayvigo in Utah is legal, with one important caveat: as a Schedule IV controlled substance, lemborexant is subject to the Ryan Haight Online Pharmacy Consumer Protection Act, which historically required an in-person evaluation before a controlled substance could be prescribed via telemedicine [12]. The DEA's temporary COVID-19 telemedicine flexibilities, which allowed initial prescribing of Schedule III and IV medications via telemedicine without a prior in-person visit, have been extended through December 31, 2025, with proposed rules for a permanent telemedicine framework under consideration at the time of writing [12].

Utah telehealth law (Utah Code Section 26-60-101 et seq.) permits a prescriber licensed in Utah to prescribe to a patient located in Utah via synchronous audio-visual telemedicine after establishing a proper patient-provider relationship, which includes a medical history and a clinical evaluation appropriate to the condition being treated [13]. An insomnia evaluation via telehealth typically includes validated screening tools such as the Insomnia Severity Index (ISI) and a review of sleep history, comorbid conditions, current medications, and prior treatment attempts.

HealthRX clinicians licensed in Utah can evaluate patients for insomnia and prescribe lemborexant via telehealth visits. Patients should be prepared to discuss prior sleep interventions, current use of other CNS depressants, and any history of parasomnia or complex sleep behaviors, because those conditions are listed as warnings in the Dayvigo prescribing information [1].

Comparing Dayvigo to Other Sleep Medications on Cost and Coverage in Utah

Dayvigo is not the only option for Utah patients with chronic insomnia, and cost comparisons are relevant to both prescriber and patient decision-making.

Zolpidem (generic) remains the most commonly prescribed sleep medication in the United States, available at most Utah pharmacies for $4 to $10 per month on generic programs. Utah Medicaid covers generic zolpidem [4]. The FDA, however, strengthened the black-box warning on zolpidem and related Z-drugs in 2019 because of serious complex sleep behaviors including sleepwalking, sleep driving, and other activities performed while not fully awake [1]. Patients who have experienced those behaviors on Z-drugs are particularly strong candidates for a DORA like lemborexant.

Suvorexant (Belsomra), the first approved DORA, carries a similar mechanism to lemborexant. Generic suvorexant is not yet available. Cash-pay prices in Utah for Belsomra are comparable to Dayvigo. The 2019 SUNRISE-1 trial directly compared lemborexant to zolpidem ER but not to suvorexant, so head-to-head DORA data are limited [8].

Low-dose doxepin (Silenor 3 mg, 6 mg) is available as a generic and is FDA-approved specifically for sleep maintenance insomnia. It appears on many Utah commercial formularies at Tier 1 or Tier 2, making it significantly cheaper for insured patients. Doxepin's tricyclic antidepressant pharmacology makes it unsuitable for patients with certain cardiac conditions or urinary retention.

Ramelteon (Rozerem) is a melatonin receptor agonist, not a controlled substance, and therefore not subject to the Ryan Haight Act telemedicine restrictions. Generic ramelteon is available and covered by most Utah Medicaid plans. Its efficacy for sleep maintenance is modest compared to lemborexant [5].

Practical Steps for Utah Patients to Minimize Dayvigo Cost

Getting the lowest possible price for Dayvigo in Utah requires working through a short checklist, because no single discount path works for every patient type.

Start by confirming your insurance status. Commercial insurance with the Eisai savings card is the best-case scenario for most patients and can bring cost to $0 for the first 12 months [7]. If you have Medicare Part D, ask your prescriber to run a formulary exception citing SUNRISE-1 data and failed alternatives [8]. Utah Medicaid patients should request a prior authorization with documented failure of at least two generic alternatives and CBT-I.

If you are uninsured or underinsured, compare cash-pay prices at multiple pharmacies using GoodRx, NeedyMeds, or RxSaver. Prices vary by $20 to $40 per month across Salt Lake County alone, so the comparison takes five minutes and is worth doing. The $85 average is a reasonable expectation, but some pharmacies quote below $70 with the right coupon code applied.

Ask your prescriber whether compounded lemborexant from a Utah-licensed 503A pharmacy is appropriate for your clinical situation. If a legitimate clinical reason exists (formulation intolerance, documented allergy to an excipient), compounding may reduce cost substantially. The prescriber must document that reason in the chart and on the prescription [10].

Finally, consider the cost of untreated chronic insomnia. A 2019 analysis in the journal Sleep estimated the annual cost of insomnia-related lost productivity in the United States at $63 billion [14]. Effective treatment of insomnia has documented downstream effects on daytime function, accident risk, and comorbid conditions including depression and cardiovascular disease [14][15].

A HealthRX-licensed Utah prescriber can review your complete sleep history, prior medication record, and insurance situation in a single telehealth visit and provide a documented lemborexant prescription or a referral to CBT-I as appropriate. New patients without prior sleep evaluation should bring a completed Insomnia Severity Index score to the visit, which takes under 5 minutes to complete online.